TGFBI corneal dystrophy is a group of genetic eye disorders caused by mutations in the TGFBI gene, resulting in abnormal ...

The gift will be used to treat and potentially cure eye diseases like macular degeneration and glaucoma, increase focus on ...

Mark Daly discusses the transformative role of AI in ophthalmology, highlighting its potential to enhance patient care and ...

Jay Chhablani, MD, explains how 3D choroidal vessel segmentation transforms ophthalmology, enhancing disease diagnosis and ...

The TEASE-1 trial reveals gildeuretinol's potential to reduce vision loss in Stargardt disease, offering hope for future ...

The ELEVATUM study explored faricimab's effectiveness in treating diabetic macular edema among underrepresented minorities, ...

Researchers share that perfluorohexylactane eye drops offer rapid relief for dry eye disease, enhancing patient comfort ...

On the heels of its FDA approval, clinicians weigh in on acoltremon’s (Tryptry) novel mechanism of action and its potential ...

At the 2025 ASCRS meeting, Dr. Sarkisian presented 3-year data on the iDose TR from the FDA clinical trial.

Kiora Pharmaceuticals has granted Senju Pharmaceutical an exclusive option to exercise rights to an exclusive development and ...

Boyer discusses a potential treatment for diabetic retinopathy and macular degeneration using suprachoroidal injections, ...

OCU400 is Ocugen’s novel modifier gene therapy for retinitis pigmentosa (RP). The OCU400 (AAV5-h NR2E3) gene therapy platform ...